Pinnacle West Asset Management Inc. Has $517,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Pinnacle West Asset Management Inc. lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,280 shares of the medical instruments supplier’s stock after purchasing an additional 60 shares during the quarter. Pinnacle West Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $517,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. State Street Corp raised its position in Becton, Dickinson and Company by 0.8% in the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock valued at $3,364,096,000 after buying an additional 106,616 shares during the last quarter. Geode Capital Management LLC raised its position in Becton, Dickinson and Company by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock valued at $1,510,050,000 after buying an additional 111,101 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Becton, Dickinson and Company by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after buying an additional 460,440 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after buying an additional 1,317,723 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after buying an additional 673,568 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 700 shares of the stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the transaction, the director now owns 36,033 shares in the company, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. The trade was a 8.01 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,544 shares of company stock worth $2,370,309. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Trading Down 0.1 %

Shares of Becton, Dickinson and Company stock opened at $230.14 on Wednesday. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The firm has a market cap of $66.08 billion, a PE ratio of 38.23, a P/E/G ratio of 1.63 and a beta of 0.40. The stock has a fifty day moving average price of $233.05 and a 200-day moving average price of $233.21. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its Board of Directors has approved a stock repurchase program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.81%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Analyst Ratings Changes

A number of equities research analysts recently commented on BDX shares. Barclays increased their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Finally, StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $278.29.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.